ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

DRD2

dopamine receptor D2 · also D2R · Dopamine receptors

15 programs in company-led studies act on DRD2, from 11 companies: 3 in phase 3, 10 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
iloperidoneruleVanda Pharmaceuticalsantagonistphase 4153 runningHTR2AChEMBL
AripiprazoleruleOtsuka–phase 41312 runningHTR1A, HTR2AChEMBL
lurasidoneruleSumitomo Pharmaantagonistphase 4522 runningHTR2AChEMBL
CabergolineruleChangchun GeneScience Pharmaceuticalagonistphase 482 running–ChEMBL
RisperidoneruleJohnson & Johnsonantagonistphase 41111 runningHTR2A, HTR2CChEMBL
paliperidoneruleJohnson & Johnsonantagonistphase 41061 runningHTR2AChEMBL
OlanzapineruleEli Lillyantagonistphase 4761 runningDRD3, DRD4, HTR2A, HTR2CChEMBL
rotigotineruleUCBagonistphase 4641 runningDRD3, DRD4ChEMBL
PramipexoleruleBoehringer Ingelheimagonistphase 4441 runningDRD3, DRD4ChEMBL
brexpiprazoleruleOtsuka–phase 4700 runningHTR1A, HTR2AChEMBL
lumateperoneruleJohnson & Johnsonantagonistphase 3256 runningHTR2A, SLC6A4ChEMBL
cariprazineruleAbbVie–phase 3414 runningDRD3ChEMBL
pridopidinerulePrilenia–phase 3102 running–ChEMBL
ABBV-932AbbVieagonistphase 2103 runningDRD3, HTR1Athe company's pipeline
zeltiproneruleJazz Pharmaceuticals–phase 233 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.